The cut-off value for interleukin 34 as an additional potential inflammatory biomarker for the prediction of the risk of diabetic complications

Biomarkers

Volumn 21, Issue 3, 2016, Pages 276-282

  Zorena, Katarzyna ^a   Jachimowicz Duda, Olga ^b   Wąż, Piotr ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b Diabetic Outpatient Clinic in Gdynia   (Poland)

Author keywords

C reactive protein; IL 34 cut off; type 2 diabetes mellitus

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 34; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER; INTERLEUKIN DERIVATIVE; INTERLEUKIN-34, HUMAN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC MICROANGIOPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HIP CIRCUMFERENCE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO; AGED; BLOOD; COMPLICATION; DIABETIC ANGIOPATHIES; INFLAMMATION; METABOLISM; PATHOLOGY; PREDICTIVE VALUE;

AGED; BIOMARKERS; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; INFLAMMATION; INTERLEUKINS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS;

EID: 84958053909     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2016.1138321     Document Type: Article

References (38)

1. Al-Shukaili A, Al-Ghafri S, Al-Marhoobi S, et al. (2013). Analysis of inflammatory mediators in type 2 diabetes patients. Int J Endocrinol 2013: 976810
2. Bermúdez V, Rojas J, Salazar J, et al. (2015). Sensitivity and specificity improvement in abdominal obesity diagnosis using cluster analysis during waist circumference cut-off point selection. J Diabetes Res 2015: 750265
3. Carpenter J, Bithell J. (2000). Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med 19: 1141-64
4. Chang EJ, Lee SK, Song YS, et al. (2014). IL-34 is associated with obesity, chronic inflammation, and insulin resistance. J Clin Endocrinol Metab 99: E1263-71
5. Chemel M, Le Goff B, Brion R, et al. (2012). Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patients. Ann Rheum Dis 71: 150-4
6. Chen Z, Buki K, Vaaraniemi J, et al. (2011). The critical role of IL34 in osteoclastogenesis. PLoS One 6: e18689
7. Daniele G, Guardado Mendoza R, et al. (2014). The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol 51: 123-8
8. Del Cañizo Gómez FJ, Fernández Pérez C, Moreno Ruiz I, et al. (2011). Microvascular complications and risk factors in patients with type 2 diabetes. Endocrinol Nutr 58: 163-8
9. DeLong ER, DeLong DM, Clarke-Pearson DL. (1988). Comparing the areas under two or more correlated receiver operating characteristic curves: a non-parametric approach. Biometrics 44: 837-42
10. ETDRS Research Group, ETDRS Report No 11. (1991). Classification of diabetic retinopathy from fluorescein angiograms. Ophthalmology 98: 807-22
11. Firdous S. (2014). Correlation of CRP, fasting serum triglycerides and obesity as cardiovascular risk factors. J Coll Physicians Surg Pak 24: 308-13
12. Greter M, Lelios I, Pelczar P, et al. (2012). Stroma-derived inerleukin 34 controls the development and maintenance of Langerhans cells and the maintenance of microglia. Immunity 37: 1050-60
13. Hafiane A, Kellett S, Genest J. (2014). Treatment options for low high-density lipoproteins. Curr Opin Endocrinol Diabetes Obes 21: 134-9
14. Halcox JP, Roy C, Tubach F, et al. (2014). C-reactive protein levels in patients at cardiovascular risk: EURIKA study. BMC Cardiovasc Disord 14: 25
15. Hwang SJ, Choi B, Kang SS, et al. (2012). Interleukin-34 produced by human fibroblast-like synovial cells in rheumatoid arthritis supports osteoclastogenesis. Arthritis Res Ther 14: R14
16. International Diabetes Federation (IDF) Diabetes. Atlas. Available at: http://www.idf.org/sites/default/files/EN-6E-Atlas-Full-0.pdf
17. Kluzek S, Arden NK, Newton J. (2015). Adipokines as potential prognostic biomarkers in patients with acute knee injury. Biomarkers 26: 1-7
18. Li Z, Jin D, Wu Y, et al. (2012). Increased serum interleukin-34 in patients with coronary artery disease. J Int Med Res 40: 1866-70
19. Matsuda M, Shimomura I. (2013). Increased oxidative stress in obesity: implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer. Obes Res Clin Pract 7: e330-41
20. McKeage K, Keating GM. (2011). Fenofibrate: a review of its use in dyslipidaemia. Drugs 71: 1917-46
21. Mora S, Ridker PM. (2006). Justification for the use of statins in primary prevention: an intervention trial evaluating rosuvastatin (JUPITER)-can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol 97: 33A-41A
22. Myśliwska J, Zorena K, Myśliwiec M, et al. (2009). The-174GG interleukin-6 genotype is protective from retinopathy and nephropathy in juvenile onset type 1 diabetes mellitus. Pediatr Res 66: 341-5
23. Ofstad AP, Gullestad L, Orvik E, et al. (2013). Interleukin-6 and activin A are independently associated with cardiovascular events and mortality in type 2 diabetes: the prospective Asker and Bærum cardiovascular diabetes (ABCD) cohort study. Cardiovasc Diabetol 12: 126. DOI: 10.1186/1475-2840-12-126
24. Pal GK, Adithan C, Ananthanarayanan PH, et al. (2013). Sympathovagal imbalance contributes to prehypertension status and cardiovascular risks attributed by insulin resistance, inflammation, dyslipidemia and oxidative stress in first degree relatives of type 2 diabetics. PLoS One 8: e78072
25. Patry-Parisien J, Shields M, Bryan S. (2012). Comparison of waist circumference using the world health organization and national institutes of health protocols. Health Rep 23: 53-60
26. Position of the Polish Diabetes Association. (2014). "Clinical recommendations for treatment of patients with diabetes". Clin Diabetol (suppl A) 3: A1-A71
27. Rathcke CN, Vestergaard H. (2009). YKL-40-an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol 8: 61. DOI: 10.1186/1475-2840-8-61
28. Report of WHO Consultation of Obesity. Geneva 3-5 June 1997. (2012 Aug 3). WHO/NUT/NCD 1998. BMC Med Res Methodol. 12: 115
29. Ridker PM, Rifai N, Rose L, et al. (2002). Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557-65
30. Rydén L, Grant PJ, Anker SD, et al. (2014). ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD-summary. Task force on diabetes, pre-diabetes, and cardiovascular diseases of the European society of cardiology (ESC); European association for the study of diabetes (EASD). Diab Vasc Dis Res 11: 133-73
31. Sacks FM, Hermans MP, Fioretto P, et al. (2014). Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation 129: 999-1008
32. Tomić M, Ljubić S, Kaštelan S, et al. (2013). Inflammation, haemostatic disturbance, and obesity: possible link to pathogenesis of diabetic retinopathy in type 2 diabetes. Mediators Inflamm 2013: 818671
33. Wegner M, Araszkiewicz A, Piorunska-Stolzmann M, et al. (2013). Association between IL-6 concentration and diabetes-related variables in DM1 patients with and without microvascular complications. Inflammation 36: 723-8
34. WHO: Definition. Diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1 (2006). Diagnosis and classification of diabetes mellitus. WHO. Geneva
35. Yeh ET, Willerson JT. (2003). Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation 107: 370-1
36. Youden WJ. (1950). Index for rating diagnostic tests. Cancer 3: 32-5
37. Zorena K, Kula M, Malinowska E, et al. (2013a). Threshold serum concentrations of tumour necrosis factor alpha (TNFα) as a potential marker of the presence of microangiopathy in children and adolescents with type 1 diabetes mellitus (T1DM). Hum Immunol 74: 75-81
38. Zorena K, Malinowska E, Raczyńska D, et al. (2013b). Serum concentrations of transforming growth factor-Beta 1 in predicting the occurrence of diabetic retinopathy in juvenile patients with type 1 diabetes mellitus. J Diabetes Res 2013: 614908